Optimized Traditional Chinese Medical Oncologic Evaluation Systerm Of Response To Treatment (TCMOES) In Advanced Non-small Lung Cancer (NSCLC)

Research backgroundThe lung cancer is a kind of relatively high malignancy grade, easily relapsing after treatment and transferred cancer. At present, it has become one of cancers with the highest morbidity and mortality to seriously threat people' s health. With the traditional chemotherapy entering into a comparatively smooth developing period, the targeted therapy has gradually entered into people's view. It is found in the present research that many targeted medicines do not kill the cancer cell to reduce its volume in the clinical just like the traditional cytotoxic drugs nor indicate the anticancer in the experiment. However, it is indicated effective during the progress period without disease and the overall survival. The traditional Chinese medicine could improve the clinical symptoms, improve the survival quality, stabilize the neoplasm and extend the life cycle in the treatment of the cancer. The curative effect of the oncotherapy widely used now:WHO and RECIST are both targeted for the neoplasm size. China Association of Chinese Medicine Cancer Branch formulated "Traditional Chinese Medical Oncologic Evaluation System of Response to Treatment (TCMOES)" (hereinafter refer to "Draft") in 2003 which integrates four indexes for curative evaluation including neoplasm size, clinical symptoms, Karnofsky and life cycle to better reflect the characteristic of the curative effect of traditional Chinese medicine to cure the cancer. It adopts the WHO standard in "Traditional Chinese Medical Oncologic Evaluation System of Response to Treatment (TCMOES)". However, through the application for more than 20 years, it is discovered that WHO standard has certain confusion in certain aspects. At present, the medical community adopts RECIST standard to evaluate the neoplasm change. In order to objectively and reasonably evaluate for the curative effect of traditional Chinese medicine for cancer treatment, many medical scientists are discussing to set up more regular and comprehensive curative evaluation of the tumor.ObjectiveThis research adopts RECIST, Draft and Optimized Draft to evaluate for the curative effect for 85 advanced non-small cell lung cancer (NSCLC) patients and makes comparison for those three kinds of results.MethodsThis research adopts RECIST, Draft and Optimized Draft to evaluate for the curative effect for 85 advanced non-small cell lung cancer (NSCLC) patients and makes comparison for those three kinds of results.Result1. According to RECIST evaluation, the inefficiency is higher than the other two curative effect evaluations and the efficiency is lower than the other two types of curative effect evaluations.2. Draft and the Optimized Draft, RECIST standard and Optimized Draft have certain relations while RECIST standard and Draft are not relevant.3. Draft and the Optimized Draft are applied for the curative effect evaluation of advanced non-small cell lung cancer (NSCLC) patients in the later stage which could better reflect the curative effect characteristic of Chinese medicine to cure the cancer.4.The Optimized Draft adopts the internationally used RECIST standard which is simpler in operation and able to act on international convention.ComclusionFor evaluating the curative effect of the Chinese medicine to cure NSCLC in later stage with the Optimized Draft, its result could better reflect the characteristic and advantage of the curative effect of the Chinese medicine. Comparing to RECIST standard, it is more objective and comprehensive. Comparing with Draft, to adopt the internationally used RECIST standard for the tumor change is easier in operation and able to act on international convention.